PRODUCT PIPELINES

Amphastar’s focus has always been on developing:

Ø	Difficult to produce products, such as emulsions and suspensions.
Ø	Generic products with a significant market, but with no available API.
Ø	New products with a unique marketing niche.
Ø	New delivery systems for well established products.

Amphastar has developed a group of generic products that are on the FDA’s shortage list.

Many of the products Amphastar has chosen to develop are products that have been off patent, but have not been pursued by other companies because they are technically difficult to develop.

Amphastar strives to improve upon existing products by:

Ø	Increasing a product's shelf life.
Ø	Reducing adverse side effects.
Ø	Loading existing, well established drugs to Amphastar's delivery systems to improve their bioavailability or safety.

Amphastar conducts R&D on a broad basis which supports its expertise in manufacturing true solution, gel, cream, emulsion, suspension, and lyophilization dosage forms.

Amphastar continues to develop and grow its pipeline as it continues to grow and diversify as a company.